Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695-1705

Blood Adv. 2022 Nov 22;6(22):5885. doi: 10.1182/bloodadvances.2021005392.
No abstract available

MeSH terms

  • Clinical Trials as Topic
  • Costs and Cost Analysis
  • Cytokine Release Syndrome* / drug therapy
  • Cytokine Release Syndrome* / etiology
  • Humans
  • Immunotherapy, Adoptive* / adverse effects